215 related articles for article (PubMed ID: 22123870)
1. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis.
Singh N; Hawley KL; Viswanathan K
Pediatrics; 2011 Dec; 128(6):e1588-95. PubMed ID: 22123870
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
Jeon GW; Oh M; Sin JB
Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
[TBL] [Abstract][Full Text] [Related]
4. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants.
Singh N; Halliday HL; Stevens TP; Suresh G; Soll R; Rojas-Reyes MX
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010249. PubMed ID: 26690260
[TBL] [Abstract][Full Text] [Related]
5. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
[TBL] [Abstract][Full Text] [Related]
6. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
Fujii A; Allen R; Doros G; O'Brien S
J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
[TBL] [Abstract][Full Text] [Related]
7. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
[TBL] [Abstract][Full Text] [Related]
8. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
[TBL] [Abstract][Full Text] [Related]
10. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.
Ramanathan R; Biniwale M; Sekar K; Hanna N; Golombek S; Bhatia J; Naylor M; Fabbri L; Varoli G; Santoro D; Del Buono D; Piccinno A; Dammann CE
J Pediatr; 2020 Oct; 225():90-96.e1. PubMed ID: 32553868
[TBL] [Abstract][Full Text] [Related]
11. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of surfactant preparations in premature infants.
Trembath A; Hornik CP; Clark R; Smith PB; Daniels J; Laughon M;
J Pediatr; 2013 Oct; 163(4):955-60.e1. PubMed ID: 23769501
[TBL] [Abstract][Full Text] [Related]
13. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
Moya F; Sinha S; Gadzinowski J; D'Agostino R; Segal R; Guardia C; Mazela J; Liu G;
Pediatrics; 2007 Jun; 119(6):e1361-70. PubMed ID: 17533176
[TBL] [Abstract][Full Text] [Related]
14. Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome.
Eras Z; Dizdar EA; Kanmaz G; Guzoglu N; Aksoy HT; Altunkaya GB; Canpolat FE; Dilmen U
Am J Perinatol; 2014 Jun; 31(6):463-8. PubMed ID: 23884719
[TBL] [Abstract][Full Text] [Related]
15. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.
Ramanathan R; Bhatia JJ; Sekar K; Ernst FR
J Perinatol; 2013 Feb; 33(2):119-25. PubMed ID: 21886094
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
Malloy CA; Nicoski P; Muraskas JK
Acta Paediatr; 2005 Jun; 94(6):779-84. PubMed ID: 16188788
[TBL] [Abstract][Full Text] [Related]
17. Calfactant: a review of its use in neonatal respiratory distress syndrome.
Onrust SV; Dooley M; Goa KL
Paediatr Drugs; 1999; 1(3):219-43. PubMed ID: 10937453
[TBL] [Abstract][Full Text] [Related]
18. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
Lamboley-Gilmert G; Lacaze-Masmonteil T;
Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
[TBL] [Abstract][Full Text] [Related]
19. Complications among premature neonates treated with beractant and poractant alfa.
Gharehbaghi MM; Sakha SH; Ghojazadeh M; Firoozi F
Indian J Pediatr; 2010 Jul; 77(7):751-4. PubMed ID: 20589459
[TBL] [Abstract][Full Text] [Related]
20. Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial.
Lemyre B; Fusch C; Schmölzer GM; Rouvinez Bouali N; Reddy D; Barrowman N; Huneault-Purney N; Lacaze-Masmonteil T
PLoS One; 2017; 12(5):e0175922. PubMed ID: 28472058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
